Who are we?
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years.
Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth.
Headquartered in Saint-Prex, Switzerland, Ferring has its own manufacturing facilities in several European countries, in South America, China, India, Israel, and USA. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Founded in 1950, Ferring now employs more than 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Drugs Disributed by Ferring Pharmaceuticals Ltd
Tocolytic Agent. Atosiban 7.5 mg/ml. Sol. FOR INJECT: 1
CONC. FOR INFUSION: 1
To start as soon as possible aft. diagn.
of preterm labour in 3 successive
stages: initial bolus dose (6.75 mg)
with 7.5 mg/ml sol. for inject., immed.
foll. by continuous high dose infus.
(300 μg/min) during 3 hrs. foll. by
lower dose (100 μg/min) for up to 45
hrs. Infus. to be performed with 7.5
mg/ml conc. sol. for infus. Tmt. not to
exceed 48 hrs. Total dose not to exceed
330 mg active substance.
To delay imminent pre-term birth in
pregn. women with reg. uterine
contracts. of at least 30 secs. durat. at
rate of ≥ 4/30 mins., cervical dilat. of 1-3
cm (multiparas: 0-3), effacement of ≥
50%; age ≥ 18 yrs., gestat. age: 24-33
completed wks; normal fetal heart rate.
C/I: Gestat. age below 24 or over 33
completed wks., prem. rupture
membranes > 30 wks gestat.,
intrauterine growth retard, abnorm.
fetal heart rate, antepartum uterine
hemorrh. req. immed. delivery,
eclampsia and severe pre-eclampsia
req. delivery, intrauterine fetal death,
suspect. intrauterine infect., placenta previa, abruptio placenta, any other cond. of mother and fetus which is
hazardous, known hypersens. to excips.
Gonadotropin. Urofollitropin (FSH) 75 IU/vial. VIAL (pwdr. for inject. + amp with solv.):
10. For S.C. inject. See lit.
Anovulatory infertility (incl. PCOD),
unresponsive to clomiphene citrate.
Controlled ovarian hyperstim. to induce
develop. multiple follicles for ART, such as
IVF, ET, GIFT and ICSI.
C/I: Tumors of pituitary/hypothalam.
glands, ovarian, uterine or mammary
carcinoma. Pregn., lact. Gyn. hemorrh. of
unknown etiology. Hypersens.
GnRH Agonist. Triptorelin Acetate 0.1 mg/ml. PFS: 0.1 mg/ml. See lit.
Lowers sexual hormones, precocious
puberty, endometriosis,
uterusleiomyoma, IVF.
GnRH Agonist. Triptorelin Acetate 3.75 mg. MICROCAPSULES C.R: 1 kit x 3.75 mg. 1
I.M. inject. mthly. See lit.
Lowers sexual hormones, precocious
puberty, endometriosis,
uterusleiomyoma, IVF.
GnRH Agonist. Triptorelin Embonate 11.25 mg. VIAL (pwdr. + solv.): 1 x 11.25 mg. 1 x
every 12 wks, I.M.
Prostat. cancer, lower. sex hormones.
